Program Information
Selective Protection of Normal Tissue by Cerium Oxide Nanoparticles During Radiation Therapy
Z Ouyang1,2*, S Yasmin-Karim2 , G Strack1 , E Sajo1 , W Ngwa1,2 , (1) University of Massachusetts Lowell, Lowell, MA, (2) Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Presentations
TU-H-CAMPUS-TeP2-5 (Tuesday, August 2, 2016) 5:00 PM - 5:30 PM Room: ePoster Theater
Purpose: Cerium oxide nanoparticles (CONPs) have unique pH dependent properties such that they act as a radical modulator. These properties may be used in radiation therapy (RT) to protect normal tissue. This work investigates the selective radioprotection of CONPs in-vitro and potential for in-situ delivery of CONPs in prostate cancer RT.
Methods: i) Normal human umbilical vein endothelial cells (HUVEC) and human prostate cancer cells (PC-3) were treated with 0 or 2 ng/mL CONPs (NP size: 5 nm). 2 Gy of 100 kVp radiation was delivered to the cells 4 hours after the CONP treatment. Cell viability was checked 48 hours later using MTS assays. ii) A prostate tumor was modeled as a 2-cm diameter sphere. CONPs were proposed to be loaded in a hollow radiotherapy fiducial marker. The concentration profile for the CONPs within the tumor was modeled with a previously validated diffusion equation employed in other studies for nanoparticles 10 nm or less.
Results: i) Without radiation, cell viability was above 90% when treated with 2 ng/mL CONPs for both HUVEC and PC-3. After irradiation, a slightly higher viability was observed in HUVEC with CONPs than the ones without CONPs, and this effect was not observed in PC-3. ii) Based on the calculations, 2 ng/mL of CONPs could be delivered to normal cells by diffusion with a 1 μg/mL initial concentration within two weeks.
Conclusion: We conclude that CONPs can provide selective radioprotection. The delivery of needed concentrations of CONPs is feasible via in-situ release from radiotherapy biomaterials (e.g. fiducials) loaded with the CONPs.
Contact Email: